CoreValve to Present at Medtech Insight's ``Investment In Innovation'' Conference.IRVINE, Calif. -- CoreValve has announced that it will present at Medtech Insight's Prestigious "Investment In Innovation (In3): A Preview of Early-Stage Medical Technology Companies" Conference, taking place February 10-11, 2005, at the Hyatt Regency Irvine in Irvine, California. CoreValve S.A. (www.corevalve.com) recently received approval from the German government to immediately commence a clinical trial of its proprietary ReValving(TM) System to non-surgically replace diseased aortic aortic pertaining to or emanating from the aorta. See also aortic arch. aortic aneurysm occurs most often in dogs, where it is caused by Spirocerca lupi larvae, turkeys and primates, causing dyspnea, cyanosis and coughing. heart valves Heart valves Valves that regulate blood flow into and out of the heart chambers. Mentioned in: Heart Failure in patients who are contraindicated for open-heart surgery. Previously, CoreValve received 'local' IRB IRB See: Industrial Revenue Bond approval from The Heart Center, Seigburg, Germany, where the clinical trial will take place. The principal investigator will be Eberhard Grube, M.D., chief of cardiology at The Heart Center and a consulting professor of medicine at Stanford University. Professor Grube will perform the ReValving procedure in the cardiac catheterization Cardiac Catheterization Definition Cardiac catheterization (also called heart catheterization) is a diagnostic procedure which does a comprehensive examination of how the heart and its blood vessels function. ("cath") laboratory at The Heart Center. "Our recent clinical trial in Asia established the fact that ReValving is, indeed, feasible to non-surgically treat the widest possible range of patients, including traditional surgical candidates. Nevertheless, in Germany -- and soon in other European countries as well -- CoreValve will initially focus these trials on high-surgical-risk patients," said Jacques Seguin, M.D., chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CoreValve, S.A. "While CoreValve's strategy is to concentrate on the heart of the market -- that is, traditional surgical candidates for aortic valve replacement Aortic valve replacement is a cardiac surgery procedure in which a patient's aortic valve is replaced by a different valve. The aortic valve can be affected by a range of diseases; the valve can either become leaky (aortic insufficiency / regurgitation) or partially blocked (aortic -- we also will be sensitive to cardiologists' appeals to treat the high-surgical-risk cases, a definitive sub-segment of the percutaneous aortic valve replacement In percutaneous aortic valve replacement (PAVR), a synthetic valve is transported to the heart through a small hole made in groin. This procedure can be compared to that performed when placing a stent, or performing balloon angioplasty. market, which we expect will ultimately fast-forward physicians' adoption of ReValving. Thus, high-surgical-risk cases will be included as we commence trials in different European countries," said Professor Seguin. "No doubt, obtaining IRB and government approval in Germany is a significant milestone in confirming ReValving as the next-generation cath lab therapy for interventional cardiology interventional cardiology Cardiology The subspecialty of cardiology dedicated to the diagnosis, medical and mechanical therapy, pre- and post-procedure management of adult patients with acute and chronic forms of cardiovascular disease amenable to catheter-based , because inclusion of leading European investigative institutions such as The Heart Center can be expected to accelerate adoption of CoreValve's ReValving technology," added Professor Seguin. Now a division of Windhover Information Inc., Medtech Insight is the leading provider of business information and market intelligence for the medical technology marketplace. To register for In3 Irvine or for more information on Medtech Insight, please call Scott Pantel at 949-219-0150 or 888-290-2225 toll-free in the U.S., e-mail sales@medtechinsight.com, or visit www.medtechinsight.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion